L
LENZ Therapeutics, Inc. (LENZ)
NMS – Real Time Price. Currency in USD
7.91
-2.08 (-20.82%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
7.91
-2.08 (-20.82%)
At close: May 12, 2026, 4:00 PM EDT
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
| Name | Position |
|---|---|
| Kris Gambelin | Senior Vice President of Regulatory & Clincal Operations |
| Mr. Daniel R. Chevallard CPA | Chief Financial Officer |
| Mr. David Choromanski | Vice President of Marketing |
| Mr. Domenick Porfidia | Vice President of Sales |
| Mr. Evert B. Schimmelpennink | President, CEO, Secretary & Director |
| Mr. James W. McCollum | Co-Founder & Director |
| Mr. Marc G. Odrich M.D. | Chief Medical Officer |
| Mr. Shawn Olsson | Chief Commercial Officer |
| Ms. Melissa Rosness | Senior Vice President of Manufacturing Operations |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | 8-K | lenz-20260511.htm |
| 2026-04-28 | DEFA14A | a2026defa14a.htm |
| 2026-04-28 | ARS | a2025annualreporttoshareho.pdf |
| 2026-03-24 | 8-K | lenz-20260324.htm |
| 2026-01-07 | 8-K | lenz-20260107.htm |
| 2025-12-12 | 8-K | lenz-20251212.htm |
| 2025-11-05 | 8-K | lenz-20251105.htm |
| 2025-11-05 | 10-Q | lenz-20250930.htm |
| 2025-10-08 | 8-K | lenz-20251008.htm |
| 2025-09-30 | 8-K | lenz-20250930.htm |